Welcome : Guest

Dimension Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Dimension Therapeutics, Inc., which is principally involved in Gene Therapy Business. Illustrated with 26 tables, the report showcases the company's key markets and market position as against its competitors operating in the industry.

Code: PCP-66046
Price: $1300
Company Type: Public
Pages: 27
Date: January 2017
Market Data Tables: 26

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Gene Therapy......2
Table 1: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......2
Table 2: Gene Therapy Clinical Trials Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Phase I, n=1183, Phase I/II, n=384, Phase II, n=330, Phase II/III, n=20 and Phase III, n=74......3
Hemophilia......4
Table 3: Hemophilia Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Hemophilia A, Hemophilia B, Inhibitor, and Von Willebrand Disease......4
Table 4: Hemophilia Diagnosis and Treatments Rates by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Diagonised, Pristine Joints, Prophylactic, Treated, and Others......5
Table 5: Haemophilia by Severity Stage Worldwide (2015) - Percentage Market Share Breakdown by No. of Patients for Mild, Moderate and Severe......6
Table 6: Haemophilia Patient Population by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Haemophilia A (Factor VIII Deficiency) and Haemophilia B (Factor IX Deficiency)......7
Table 7: Continuous Prophylaxis (Moderate) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......8
Table 8: Continuous Prophylaxis Treatment (Severe) for Hemophilia A Patients by Age Group Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......9
Table 9: On-Demand (Moderate Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......10
Table 10: On-Demand (Severe Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......11
Table 11: Haemophilia B - Recombinant (Benefix) Sales by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Emerging Markets, Europe, US, and Others......12
Table 12: Immune Tolerance Therapy (Patient) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......13
Table 13: Intermittent Prophylaxis (Moderate Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......14
Table 14: Intermittent Prophylaxis (Severe Patient Equivalent) Treatment for Hemophilia A Patients by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for 0-12, 13-21 and 22+......15
Table 15: U.S. Hemophilia Market Patients Treated/Year (2014)......16
Factor IX (FIX)......17
Table 16: Factor IX (FIX) Consumption by Category Worldwide (2015) - Percentage Market Share Breakdown by Volume for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......17
Table 17: Factor IX (FIX) Sales by Category Worldwide (2015) - Percentage Market Share Breakdown by Value for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......18
Table 18: Factor IX (FIX) Sales by Category in the US (2015) - Percentage Market Share Breakdown by Value for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......19
Table 19: Factor IX (FIX) Consumption by Category in the US (2015) - Percentage Market Share Breakdown by Volume for Plasma-Derived FIX (PD FIX) and Recombinant FIX (r-FIX)......20
Factor VIII (FVIII)......21
Table 20: Factor VIII (FVIII) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Plasma-Derived (PD FVIII) and Standard r-FVIII (Recombinant FVIII)......21
Table 21: Factor VIII (FVIII) Market by Category in the US (2015) - Percentage Share Breakdown by Volume Sales for Plasma-Derived (PD) FVIII and Standard r-FVIII (Recombinant FVIII)......22
Table 22: Factor VIII (FVIII) Market by Category in the US (2015) - Percentage Share Breakdown by Value Sales for Plasma-Derived (PD FVIII) and Standard r-FVIII (Recombinant FVIII)......23
Factor VIII (FVIII)......24
Table 23: Market Shares of Leading Factor VIII (Without Recombinant Factor) Companies in China (2014) - Percentage Breakdown by Value for China Biologic Products, Inc., Green Cross Corporation, Hualan Biological Engineering, Inc., and Shanghai RAAS Blood Products Co., Ltd.......24
Table 24: Market Shares of Leading Factor VIII (With Recombinant Factor) Companies in China (2014) - Percentage Breakdown by Value for Bayer AG, China Biologic Products, Inc., Green Cross Corporation, Hualan Biological Engineering, Inc., and Shanghai RAAS Blood Products Co., Ltd.......25
Table 25: Market Shares of Leading Factor VIII Providers in China (2015) - Percentage Breakdown by Value for China Biologic Products, Inc., Green Cross (China) Co., Ltd., Shanghai RAAS Blood Products Co., Ltd., and Others......26
Table 26: Market Shares of Leading Factor VIII Providers in the US (2015) - Percentage Breakdown by Value for Baxter International Inc., CSL Limited, Grifols, S.A., and Kedrion S.p.A......27